GH Research (GHRS) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing novel mebufotenin therapies for treatment-resistant depression (TRD).

• Lead candidates include GH001 (inhalable) and GH002 (intravenous), with proprietary delivery devices under development.

• Completed multiple Phase 1 and Phase 2 clinical trials, showing potential for ultra-rapid remission in TRD patients.

• Incorporated in Ireland, operates as a holding company with principal offices in Dublin.

• Qualifies as an emerging growth company and foreign private issuer, allowing for reduced disclosure requirements.

Financial performance and metrics

• As of December 31, 2024, 52,028,145 ordinary shares were outstanding; by February 15, 2025, this increased to 62,028,145 due to a public offering.

• In 2023, 7,296 shares were issued upon option exercise under the share option plan.

Use of proceeds and capital allocation

• Net proceeds from future offerings intended for research, clinical and technical development, working capital, capital expenditures, and general corporate purposes.

• Management retains significant discretion over allocation of funds.